Your browser doesn't support javascript.
loading
Dissemination of Misinformative and Biased Information about Prostate Cancer on YouTube.
Loeb, Stacy; Sengupta, Shomik; Butaney, Mohit; Macaluso, Joseph N; Czarniecki, Stefan W; Robbins, Rebecca; Braithwaite, R Scott; Gao, Lingshan; Byrne, Nataliya; Walter, Dawn; Langford, Aisha.
Afiliação
  • Loeb S; Department of Urology, New York University, New York, NY, USA; Department of Population Health, New York University, New York, NY, USA; Manhattan VA Medical Center, New York, NY, USA. Electronic address: stacyloeb@gmail.com.
  • Sengupta S; Eastern Health Clinical School, Monash University, Box Hill, Australia.
  • Butaney M; Royal College of Surgeons in Ireland, Dublin, Ireland.
  • Macaluso JN; LSU Health Center, Department of Urology & LSU Health Foundation, New Orleans, LA, USA.
  • Czarniecki SW; HIFU Clinic, Prostate Cancer Center, Warsaw, Poland.
  • Robbins R; Department of Population Health, New York University, New York, NY, USA.
  • Braithwaite RS; Department of Population Health, New York University, New York, NY, USA.
  • Gao L; Department of Urology, New York University, New York, NY, USA.
  • Byrne N; Department of Urology, New York University, New York, NY, USA; Department of Population Health, New York University, New York, NY, USA; Manhattan VA Medical Center, New York, NY, USA.
  • Walter D; Department of Urology, New York University, New York, NY, USA; Department of Population Health, New York University, New York, NY, USA; Manhattan VA Medical Center, New York, NY, USA.
  • Langford A; Department of Population Health, New York University, New York, NY, USA.
Eur Urol ; 75(4): 564-567, 2019 04.
Article em En | MEDLINE | ID: mdl-30502104
ABSTRACT
YouTube is a social media platform with more than 1 billion users and >600000 videos about prostate cancer. Two small studies examined the quality of prostate cancer videos on YouTube, but did not use validated instruments, examine user interactions, or characterize the spread of misinformation. We performed the largest, most comprehensive examination of prostate cancer information on YouTube to date, including the first 150 videos on screening and treatment. We used the validated DISCERN quality criteria for consumer health information and the Patient Education Materials Assessment Tool, and compared results for user engagement. The videos in our sample had up to 1.3 million views (average 45223) and the overall quality of information was moderate. More videos described benefits (75%) than harms (53%), and only 50% promoted shared decision-making as recommended in current guidelines. Only 54% of the videos defined medical terms and few provided summaries or references. There was a significant negative correlation between scientific quality and viewer engagement (views/month p=0.004; thumbs up/views p=0.015). The comments section underneath some videos contained advertising and peer-to-peer medical advice. A total of 115 videos (77%) contained potentially misinformative and/or biased content within the video or comments section, with a total reach of >6 million viewers. PATIENT

SUMMARY:

Many popular YouTube videos about prostate cancer contained biased or poor-quality information. A greater number of views and thumbs up on YouTube does not mean that the information is trustworthy.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Gravação em Vídeo / Comunicação / Internet / Disseminação de Informação / Informação de Saúde ao Consumidor / Mídias Sociais Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Limite: Humans / Male Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Gravação em Vídeo / Comunicação / Internet / Disseminação de Informação / Informação de Saúde ao Consumidor / Mídias Sociais Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Limite: Humans / Male Idioma: En Ano de publicação: 2019 Tipo de documento: Article